At the 2025 AMCP annual meeting in Houston, John M. O'Brien, Pharm.D., M.P.H., president and CEO of the National ...

Wayritz (rilzabrutinib) and Myqorzo (aficamten) were on the list of drugs that were expected to be approved by the FDA in the ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

At Cigna Healthcare, 2026 will be a year defined by making healthcare simpler, more affordable and more intuitive for the ...

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Higher Air Pollution and Extreme Weather Linked to Adult Atopic Dermatitis Climate change and air pollution are growing ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have ...

Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer ...